|
|
Weekly Digest
August 25, 2026
Volume 5, Issue 4
|
|
What’s Inside This Week
Two independent testing reports landed within 24 hours of each other and put supplement potency squarely back in the national conversation. Consumer Reports found that most prenatal multivitamins it tested did not deliver the nutrient levels printed on their labels, while NOW Foods reported that nearly half the vitamin C gummies it purchased on Amazon contained little to no detectable vitamin C. Both findings arrived as the industry absorbed a second major development, President Trump’s nomination of Dr. Heidi Overton to lead the FDA, a choice trade groups describe as a largely unknown quantity on dietary supplement policy. Elsewhere this week, the FDA flagged another spiked weight loss product sold as a supplement, a proposed class action challenged omega-3 label claims, regulators and analysts continued to weigh liver injury signals tied to enhanced bioavailability turmeric, and the intoxicating hemp THC ban returned to the congressional agenda ahead of the House’s August 31 return.
|
|
|
|
Supplement Quality & Label Accuracy
|
|
Consumer Reports | August 19, 2026
Consumer Reports tested 17 widely sold prenatal multivitamins and found only two met potency standards for every nutrient measured, with folic acid shortfalls drawing the most concern. All 17 products cleared the group’s safety limits for arsenic, lead, cadmium and mercury, making this a label accuracy finding rather than a contamination finding. CR ties the gap directly to DSHEA’s framework, noting that prenatals face no FDA premarket approval and that no federal standard defines what a prenatal supplement must contain.
|
|
|
Nutritional Outlook | August 20, 2026
The industry read on the Consumer Reports study reports that 32 percent of 126 nutrient measurements fell outside USP tolerance ranges, with gummy formats showing the widest variance and one product delivering just 28 percent of its labeled folic acid. The Council for Responsible Nutrition pushed back, noting that USP tolerances are voluntary for products that are not USP verified and that falling outside them is not a federal violation. The article connects the findings to the 2023 GAO prenatal report and GAO’s still unresolved recommendation that Congress grant FDA additional authority over supplement registration and labeling.
|
|
|
NutraIngredients-USA | August 20, 2026
NOW Foods and ISO 17025 accredited Alkemist Labs tested 25 vitamin C gummy brands purchased on Amazon and found that only 13 met label claim, while 12 contained little to no detectable vitamin C. Five products claiming 1,000 mg or more per gummy measured under 2 mg, less than one percent of the stated amount. NOW’s Dan Richard said the company has submitted more than 20 rounds of failing results to both Amazon and the FDA without meaningful action, and was told the agency will not pursue potency issues absent a reported health problem.
|
|
|
SupplySide Supplement Journal | August 24, 2026
Formulation and analytical experts responded to the NOW findings by explaining why gummies fail testing so often, noting the format now accounts for roughly a quarter of US supplement market share. Pectin and gelatin bases, colorants and heavy sugar loads interfere with extraction, requiring cryo-grinding with dry ice before accurate HPLC analysis. NOW’s Dan Richard said most brands skip shelf life stability testing entirely, a direct cGMP exposure under 21 CFR Part 111, which requires manufacturers to substantiate label claims through expiration.
|
|
|
|
|
FDA Leadership & the Road Ahead
|
|
NPR | August 20, 2026
President Trump announced the nomination of Dr. Heidi Overton, currently deputy assistant to the president for domestic policy, to serve as FDA commissioner, filling the vacancy left by Marty Makary’s resignation in May. The agency’s roughly 18,000 staff regulate food, drugs, devices, tobacco, cosmetics and dietary supplements. Senators Patty Murray and Bill Cassidy have already signaled opposition or concern, setting up a contested confirmation that will determine who oversees FDA’s pending supplement and GRAS initiatives.
|
|
|
NutraIngredients-USA | August 20, 2026
The trade reaction to the Overton nomination was cautious, with NPA’s Dan Fabricant calling her “somewhat of a blank slate” and questioning whether she will assess supplements objectively. AHPA’s Graham Rigby offered support based on her hemp and CBD policy work at the Domestic Policy Council, while CHPA’s Scott Melville pointed to her interest in prescription to over the counter switches. The nomination lands with live supplement dockets pending, including the proposed mandatory GRAS notification rule and unresolved questions about how FDA will treat peptides as dietary ingredients.
|
|
|
|
|
FDA Enforcement & Product Safety
|
|
U.S. Food and Drug Administration | August 18, 2026
FDA laboratory analysis found the weight loss product Esbelta Intense Loss spiked with sibutramine, desmethyl sibutramine, benzyl sibutramine and sildenafil, none of which appear on the label. Sibutramine was withdrawn from the US market over cardiovascular safety concerns, and sildenafil can dangerously lower blood pressure in consumers taking nitrates. The agency issued a companion notification the same day for Esbelta Chupapanza Flat Belly, sold by the same online seller and found to contain phenolphthalein, underscoring how spiked products marketed as supplements persist until FDA testing catches them.
|
|
|
NutraIngredients-USA | August 24, 2026
This chronology traces regulator actions on rare liver injury linked to concentrated turmeric and curcumin, from Italy’s 2019 hepatitis cluster through France’s daily intake limit, Australia’s TGA advisory and Health Canada’s 2025 mandatory cautionary labeling. The recurring theme is that enhanced bioavailability formulations using piperine, phytosomes, micelles or cyclodextrins may invalidate the conventional curcumin intake benchmark, an ingredient identity question that goes to the heart of NDI and GRAS safety dossiers. USP’s dietary supplements expert committee has recommended adding a hepatotoxicity caution to its turmeric monographs, while an FDA official raised whether adulteration with synthetic curcuminoids or contaminants contributed to reported cases.
|
|
|
|
|
Claims, Advertising & Litigation
|
|
NutraIngredients-USA | August 24, 2026
After a New York Times investigation identified hundreds of AI generated wellness personas, including fake doctors, promoting supplements to US consumers, advertising regulators made clear that substantiation and endorsement rules apply identically to synthetic spokespeople. NAD’s Phyllis Marcus and Apex Compliance’s Asa Waldstein noted that FTC health claim guidance and the consumer reviews and testimonials rule can reach AI avatars, and that an “AI generated” disclosure does not cure an unsupported or disease claim. CRN responded that fraudulent marketing and illegal disease claims are already violations of law, and renewed its call for a mandatory FDA product registry alongside greater FDA and FTC enforcement resources.
|
|
|
NutraIngredients-USA | August 19, 2026
Quten Research Institute faces a proposed class action in the Southern District of California alleging that Qunol Ultra Omega-3 Fish Oil delivers roughly 404 mg of omega-3 per two capsule serving against a front label declaration of 1,000 mg. Apex Compliance’s Asa Waldstein said label versus assay mismatches are inexpensive for plaintiffs’ firms to bring, and warned that brands must build in ingredient overages so claims hold through expiration, a documentation obligation under 21 CFR Part 111. The complaint also cites earlier Consumer Reports testing, a sign that plaintiffs’ attorneys are mining published third party results for targets. The allegations remain unproven.
|
|
|
|
|
Hemp, Kratom & Botanical Policy
|
|
Roll Call | August 24, 2026
House Freedom Caucus Chairman Andy Harris is pushing to strip the Senate passed one month delay of the intoxicating hemp ban from the continuing resolution, setting up a floor fight when the House returns on August 31. Under current law the hemp definition shifts to a total THC standard on November 12, 2026, capping hemp derived products at 0.4 mg total THC per container, a threshold the US Hemp Roundtable says would make most cannabinoid products unlawful. Competing framework bills would instead grant FDA rulemaking authority over cannabinoid limits, leaving supplement and functional beverage formulators without settled ingredient rules.
|
|
|
Nutritional Outlook | August 18, 2026
Botanical brand Vivazen launched a retailer compliance program and product testing database in response to DEA’s move on July 1 to temporarily place 7-hydroxymitragynine and three related compounds into Schedule I. The scheduling targets synthetic, high concentration 7-OH found in adulterated supplements and beverages rather than botanical kratom leaf, and both the American Kratom Association and the Natural Products Association supported the action. The initiative reflects a familiar industry pattern of self policing when a botanical category risks being pushed outside the dietary supplement definition altogether.
|
|
|
Your Voice Matters
FDA’s proposed mandatory GRAS notification rule is open for public comment, and the Senate will soon weigh a new FDA commissioner whose views on dietary supplements remain undefined. Both outcomes will shape how DSHEA is enforced for years. Add your comment and contact your senators today.
|
|
|
DSHEA Preservation Alliance
Powered by PICXM
|
|
